Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.2K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.2K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

4.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.6K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

644
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
644
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study.

Journal of Alzheimer's disease : JAD·2026
Same author

Pathology and Genetics in a Global Cohort of Parkinsonian Disorders.

JAMA neurology·2026
Same author

Dysregulated TIE-2 expression is associated with blood-brain barrier leakiness and Alzheimer's disease-related neuropathology.

Brain pathology (Zurich, Switzerland)·2026
Same author

Urine and cerebrospinal fluid biomarkers for early glioma detection: a systematic review.

Diagnostic and prognostic research·2026
Same author

Repurposing drugs for the prevention of vascular dementia using evidence from drug target Mendelian randomization.

Nature aging·2026
Same author

New perspectives on VEGF signalling in Alzheimer's disease.

Brain pathology (Zurich, Switzerland)·2026

Related Experiment Video

Updated: Feb 25, 2026

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
10:36

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption

Published on: June 20, 2017

9.1K

Cerebral Aβ40 and systemic hypertension.

Hannah M Tayler1, Jennifer C Palmer1, Taya L Thomas1

  • 11 School of Clinical Sciences, University of Bristol, Bristol, UK.

Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|August 8, 2017
PubMed
Summary
This summary is machine-generated.

Amyloid-beta (Aβ) infusion into the brain exacerbates hypertension in rats by affecting autonomic activity. This suggests Aβ may contribute to mid-life hypertension seen in Alzheimer's disease patients.

Keywords:
Alzheimer diseaseDahl salt-sensitive ratsamyloid-beta peptidesbaroreflexhypertension

More Related Videos

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

104.7K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.7K

Related Experiment Videos

Last Updated: Feb 25, 2026

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
10:36

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption

Published on: June 20, 2017

9.1K
A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

104.7K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.7K

Area of Science:

  • Neuroscience
  • Cardiovascular Science
  • Alzheimer's Disease Research

Background:

  • Mid-life hypertension and reduced cerebral blood flow are potential early signs of Alzheimer's disease (AD).
  • Amyloid-beta (Aβ) accumulation in AD is linked to increased brain endothelin-1, but its effect on systemic blood pressure is unknown.

Purpose of the Study:

  • To investigate if intracerebroventricular infusion of Aβ peptide affects blood pressure in Dahl salt-sensitive rats.

Main Methods:

  • Infusion of Aβ peptide into the cerebrospinal fluid of rats.
  • Utilizing Dahl salt-sensitive rats, some on a high-salt diet to induce hypertension, others normotensive.
  • Monitoring blood pressure and analyzing spectral density and baroreflex gain.

Main Results:

  • Intracerebroventricular Aβ infusion significantly increased blood pressure in hypertensive rats (p < 0.0001).
  • No blood pressure change was observed in normotensive rats.
  • Hypertension increase was linked to autonomic imbalance and reduced baroreflex sensitivity.

Conclusions:

  • Intracerebral Aβ can worsen hypertension by modulating autonomic activity.
  • This suggests that hypertension in individuals who later develop Alzheimer's disease might be a physiological response to Aβ-related cerebral hypoperfusion.